Raised charges and Covax deals on order books of Pfizer, BioNTech, Moderna and AstraZeneca
Two US companies, Pfizer and Moderna, have raised the prices of their Covid-19 vaccines after data from clinical trials showed their mRNA formula was more effective than cheaper vaccines from Britain’s AstraZeneca and the American drugs maker Johnson & Johnson.
AstraZeneca and Johnson & Johnson have pledged to provide their doses on a not-for-profit basis until the pandemic ends.
Continue reading...Co-creator of the Oxford/AstraZeneca jab hopes it will inspire young girls to enter Stem careers
Prof Sarah Gilbert has had quite a year. The co-creator of the Oxford/AstraZeneca jab has been made a dame, been given an emotional standing ovation at Wimbledon – and now a Barbie doll has been made in her honour.
Gilbert, who led the development of the Covid vaccine at Oxford University, said she initially found the gesture “very strange” but hoped it would inspire young girls to work in science, technology, engineering and mathematics (Stem).
Continue reading...Amid bemusement from scientists at the deluge of often undeserved criticism, the Guardian pieces together the story behind the vaccine’s successes and failures
In January 2020, when most of the world slept soundly in ignorance of the pandemic coming its way, a group of scientists at Oxford University got to work on a vaccine to save the planet. They wanted it to be highly effective, cheap, and easy to use in even the poorest countries.
Prof Sarah Gilbert, Prof Andrew Pollard and others pulled it off. With speed crucial, they designed it and launched into trials before bringing in a business partner. The giant Anglo-Swedish pharmaceutical company AstraZeneca would manufacture it, license it around the world – and not make a profit until the pandemic was over.
Continue reading...Oxford University trial reports cocktail of manmade antibodies reduces fatalities by a fifth
A new drug has been found to cut Covid deaths by a fifth among the sickest patients in hospital and may change official practice so that every patient with coronavirus will have an antibody test before they are admitted.
The Recovery trial based at Oxford University has found a third drug that can help Covid patients recover in hospital – but this one is the first to tackle the virus itself, rather than the inflammation that develops in the later stages of the disease.
Continue reading...Exclusive: commission’s finding follows number of protests over colonial legacy at Oriel College
A independent commission set up to examine the future of Oxford University’s controversial statue of British imperialist Cecil Rhodes has recommended its removal.
The commission was set up last June after Oxford University’s Oriel College voted in favour of removing its statue. The commission was asked to look into the issue after a statue of the slave trader Edward Colston was torn down in Bristol at the height of last summer’s Black Lives Matter protest.
Continue reading...Vaccine developed by scientists at Jenner Institute, Oxford, shows up to 77% efficacy in trial over 12 months
A vaccine against malaria has been shown to be highly effective in trials in Africa, holding out the real possibility of slashing the death toll of a disease that kills 400,000 mostly small children every year.
The vaccine, developed by scientists at the Jenner Institute of Oxford University, showed up to 77% efficacy in a trial of 450 children in Burkina Faso over 12 months.
Continue reading...UK researchers find link between regular meat intake and nine non-cancerous illnesses
Eating meat regularly increases someone’s risk of developing heart disease, diabetes, pneumonia and other serious illnesses, research has found.
It is already known that intake of red and processed meat heightens the risk of being diagnosed with bowel cancer. But these findings are the first to assess whether meat consumption is linked to any of the 25 non-cancerous illnesses that most commonly lead to people being admitted to hospital in the UK.
Continue reading...A year ago, two scientists began work on the response to a new virus. Now, as their vaccine is being given to millions, they tell of their incredible 12 months
Exactly a year ago, Oxford University scientists launched a joint enterprise that is set to have a profound impact on the health of our planet. On 11 February, research teams led by Professor Andy Pollard and Professor Sarah Gilbert – both based at the Oxford Vaccine Centre – decided to combine their talents to develop and manufacture a vaccine that could protect people from the deadly new coronavirus that was beginning to spread across the world.
A year later that vaccine is being administered to millions across Britain and other nations and was last week given resounding backing by the World Health Organization. The head of the WHO’s department of immunisation, vaccines and biologicals, Professor Kate O’Brien, described the jab as “efficacious” and “an important vaccine for the world”.
Continue reading...Scientists say it offers only slightly lower protection compared with original Covid
The Covid vaccine developed by the University of Oxford and AstraZeneca is nearly as effective against the Kent variant as it is against older forms of the virus, according to preliminary research results.
Researchers analysed swabs from trial volunteers who developed asymptomatic or symptomatic infections to determine which variant of the virus they had caught after receiving the vaccine or a control jab.
Continue reading...One jab could also offer protection of up to 76% for up to 12 weeks, a new study shows
One dose of the Oxford/AstraZeneca vaccine provides sustained protection against Covid for at least three months and cuts transmission of the virus by two-thirds, according to research that appears to support the UK’s decision to delay booster shots.
Analysis of fresh data from three trials found that the first shot conferred on average 76% protection against symptomatic infections from three weeks until 90 days, and reduced transmission of the disease by 67%.
Continue reading...Analysis: Drug company and scientific partners at Oxford University have strongly pushed back against German press report
A row has broken out after German newspapers suggested the Oxford/AstraZeneca vaccine might have a lower efficacy among the over-65s. Below we take a look at the claims, and whether we should be concerned.
Continue reading...After growing up in a Zimbabwe convulsed by the legacy of colonialism, when I got to Oxford I realised how many British people still failed to see how empire had shaped lives like mine – as well as their own
There was no single moment when I began to sense the long shadow that Cecil John Rhodes has cast over my life, or over the university where I am a professor, or over the ways of seeing the world shared by so many of us still living in the ruins of the British empire. But, looking back, it is clear that long before I arrived at Oxford as a student, long before I helped found the university’s Rhodes Must Fall movement, long before I even left Zimbabwe as a teenager, this man and everything he embodied had shaped the worlds through which I moved.
I could start this story in 1867, when a boy named Erasmus Jacobs found a diamond the size of an acorn on the banks of the Orange river in what is now South Africa, sparking the diamond rush in which Rhodes first made his fortune. Or I could start it a century later, when my grandfather was murdered by security forces in the British colony of Rhodesia. Or I could start it today, when the infamous statue of Rhodes that peers down on to Oxford’s high street may finally be on the verge of being taken down.
Continue reading...An 82-year-old retired maintenance manager has become the first person in the world outside clinical trials to receive the vaccine developed by Oxford University and AstraZeneca.
Brian Pinker, a dialysis patient, received the jab at 7.30am on Monday from Sam Foster, a nurse at Churchill hospital, part of the Oxford University hospitals NHS foundation trust.
With jab to be administered to public for first time, we look at key questions about its rollout
The biggest vaccination programme in the UK’s history will receive a major boost on Monday, with the first use of the Oxford/AstraZeneca Covid vaccine. Here we look at some key questions about how it will be deployed in England.
Continue reading...We look at how the introduction of a new vaccine in the fight against Covid will work
The Oxford/AstraZeneca vaccine is central to the government’s plans for ending social distancing in the UK and returning to some sort of normality. It has invested in seven different vaccines, but the biggest order is for 100m doses of the AstraZeneca jab, most of which will be manufactured in the UK. While the prime minister was jubilant that the UK was first in the world to approve the Pfizer/BioNTech vaccine, he is now able to claim a British triumph. More to the point is the ease of use of the AstraZeneca vaccine. Unlike Pfizer’s, it does not have to be kept in the long term at -70C. Pfizer’s vaccine can be stored in a fridge for five days, but AstraZeneca’s can be kept for months at fridge temperature, which is 2-8C and will be easy to take to care homes to administer to residents, the first priority group for vaccination.
Continue reading...From a small discovery to producing at scale, photojournalist David Levene documents the groundbreaking work of the scientists of Oxford University during the development of a vaccine which is now poised for approval by medicines regulators
From the moment the coronavirus spilled out of China and spread around the world, the great hope for the return of normal life lay with safe and effective vaccines. While wearing masks and washing hands helped to reduce the flood of infections, they would never be enough to hold back the tide. Social distancing – a phrase that does nothing to convey the hardship of the act – suppresses the virus, no doubt. But what kind of life is a life lived apart?
Continue reading...UK and Russian scientists to explore whether vaccines given together improves efficacy
UK and Russian scientists are to test whether combining shots of the Oxford/AstraZeneca and Sputnik V coronavirus vaccines could result in better protection than two doses of the same one.
Trials will start by the end of the year, the Russian Direct Investment Fund (RDIF), which funded the development of the Sputnik V vaccine by Russia’s Gamaleya Institute, said on Friday. AstraZeneca confirmed that it was considering how it could assess combinations of different vaccines, and would soon begin exploring with the Gamaleya Institute whether their two vaccines could be successfully combined.
Continue reading...Exclusive: Life expectancy has regressed to 2010 levels, say scientists, with poor hardest hit
The Covid-19 pandemic has cut life expectancy in England and Wales by roughly a year, scientists have estimated, reversing gains made since 2010.
A study, conducted by Oxford researchers, found that life expectancy at birth (LEB) had fallen by 0.9 and 1.2 years for females and males relative to 2019 levels respectively.
Continue reading...We trace the extraordinary research effort, from the discovery of the virus’s structure to the start of inoculations this week
In the early afternoon of 3 January this year, a small metal box was delivered to the Shanghai Public Health Clinical Centre addressed to virus expert Prof Zhang Yongzhen. Inside, packed in dry ice, were swabs from a patient who was suffering from a novel, occasionally fatal respiratory illness that was sweeping the city of Wuhan. Exactly what was causing terrifying rises in case numbers, medical authorities wanted to know? And how was the disease being spread?
Related: ‘I worked so hard in the lab. I cried when the news came’
Continue reading...Oxford/AstraZeneca planning new trial of lower-dose jab to see how well it works in older people
Concerns around the efficacy of the Oxford University/AstraZeneca coronavirus jab in older people could lead to different age groups being given different vaccines, experts have said.
The partners announced last week that the vaccine had a 70% efficacy overall. For most trial participants – given two full doses, spaced a month apart – the efficacy was 62%, but for 3,000 participants mistakenly given half a dose for their first jab, the efficacy was 90%. No participants, regardless of dosing, developed severe Covid or were hospitalised with the disease.
Continue reading...